Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02441517 · ClinicalTrials.gov registry record · Phase 4
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Phase 4 study, sponsored by Astellas Pharma Global Development.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT02441517 is a Phase 4 study that was terminated before completion, run by Astellas Pharma Global Development. The registered enrollment target is 4 participants.
The verdict
NCT02441517, a Phase 4 study, was terminated before completion, sponsored by Astellas Pharma Global Development.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of the study was to understand if there is benefit in treatment with a medicine called enzalutamide in the re-treatment setting. Patients must have been previously treated with enzalutamide in the pre-chemotherapy setting for a minimum of 8 months and have disease progressed, followed by docetaxel and/or cabazitaxel for at least 4 cycles.
Interventions
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2017-03-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02441517
The ClinicalTrials.gov registry entry for NCT02441517 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enzalutamide is the first listed.
NCT02441517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02441517 about?
NCT02441517 is a clinical study titled "A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment". The purpose of the study was to understand if there is benefit in treatment with a medicine called enzalutamide in the re-treatment setting. Patients must have been previously treated with enzalutamide in the pre-chemotherapy setting for a minimum of 8 months and have disease progressed, followed by...
What is the current status of trial NCT02441517?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2015-10-28. Estimated completion is 2017-03-15.
What interventions are being tested in trial NCT02441517?
The interventions under investigation include: Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02441517?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.